MaaT Pharma SA (EPA:MAAT)

Market Cap	138.87M +36.1%
Revenue (ttm)	3.92M +52.5%
Net Income	-31.13M
EPS	-2.15
Shares Out	18.82M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	85,710
Average Volume	159,688
Open	7.70
Previous Close	7.68
Day's Range	7.24 - 7.76
52-Week Range	3.55 - 8.62
Beta	0.22
RSI	59.45
Earnings Date	Mar 30, 2026

About MaaT Pharma

MaaT Pharma SA, a late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival. Its products pipeline includes MaaT013, that is in pivotal phase 3 clinical trial for the treatment of acute graft versus host diseases with gastrointestinal involvement; MaaT033, which is in phase 2b clinical trial for the improvement of survival at 12 months for patients with blood cancer receiving allogenic hematopoietic stem cell transplantation; and MaaT03X for the treatment...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 65
• Stock Exchange: Euronext Paris
• Ticker Symbol: MAAT

Financial Performance

In 2024, MaaT Pharma's revenue was 3.22 million, an increase of 44.34% compared to the previous year's 2.23 million. Losses were -28.90 million, 46.6% more than in 2023.